tbuckley/cabot-search huggingface dataset:
Abstract 14838: Novel Transcription Regulation in the Hypertrophied Myocardium via Nuclear Galpha16 Subunit and Activator of G-Protein Signaling (AGS)
Authors: Motohiko Sato, Masaharu Hiraoka, Hiroko Suzuki, Yunzhe Bai, Satoshi Okumura, Mary J Cismowski, Stephen M Lanier, Yoshihiro Ishikawa
Journal: Circulation (2010)

Cell signaling via heterotrimeric G-proteins is involved in the development of cardiac hypertrophy. In addition to G-protein coupled receptors, there exist receptor-independent regulators for heterotrimeric G-proteins which provide alternative signal input that may be involved in the adaptation process of cells to various stresses. As a part of an effort to identify such entities in cardiovascular diseases, we used a functional screen to identify receptor-independent activators of G-protein signaling (AGS) in the hypertrophied mouse heart induced by transverse aortic constriction. We identified three MITF/TFE transcription factors, TFE3, MITF, and TFEB, as novel AGS proteins for Gα16. TFE3 formed a complex with Gα16 but not Gαi3, Gαs, or Gαq in cells. TFE3 activated Gα16 in the absence of receptor stimulation but not other Gα subunits. TFE3 had no influence on receptor-mediated Gα16 signaling in the plasma membrane, however, TFE3 induced translocation of Gα16 to the nucleus. Interestingly, the accumulatio...
Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol (<sup>99m</sup>Tc-DTPA) scintigraphy
Authors: E. Azambuja, J. F. Fleck, S. S. Menna Barreto, R. D. Cunha, R. G. Batista
Journal: Journal of Clinical Oncology (2004)

4600 Background: To investigate lung toxicity in patients treated with chemotherapy containing bleomycin using 99mTc-DTPA scintigraphy Methods: Twelve non-smokers chemo-naïve patients (10 testis cancer, 1 ovary germ cell tumor, 1 Hodgkin's Disease) with no clinical or radiological evidence of pulmonary disease treated with bleomycin-based chemotherapy were tested with 99mTc-DTPA scintigraphy and pulmonary function tests before the first cycle and every 3 weeks until the third month after the end of chemotherapy (bleomycin's total cumulative dose 347.9 mg). Results: The descriptive statistics for the tests is shown in the table below. The pretreatment values of scintigraphy (T1/2 74.93 minutes) were significantly higher than those obtained after total dose bleomycin (T1/2 50.38 minutes) (P<0.001). Comparing pretreatment and post-treatment scintigraphies, the mean values decreased mainly after 256.5 mg of bleomycin's total dose. There were no difference in diffusing lung carbon monoxide (DLCO), Forced vital capacity (FVC), forced inspiratory volume at 1st second (FEV1), total lung capacity (TLC), and residual volume (RV). Conclusions: We conclude that cumulative bleomycin doses are related to increasing lung toxicity in every cycle of chemotherapy and that 99mTc-DTPA scintigraphy is able to quantify pulmonary toxicity even before the development of clinical signs and earlier than the pulmonary function tests or the CO diffusing. No significant financial relationships to disclose.
Abstract 718: Head-to-Head Comparison of Apical Rotation versus Mitral Annular Systolic Velocity for Estimation of Global Left Ventricular Contractility
Authors: Won-Jang Kim, Jeong-Sook Seo, Sun Yang Min, Jong-Min Song, Jae-Joong Kim, Seong-Wook Park, Jae-Kwan Song
Journal: Circulation (2008)

We sought to test whether mitral annular systolic velocity by tissue Doppler (S′) and apical rotation by speckle tracking echocardiography (AR) can represent global left ventricular (LV) contractility. We measured AR and S′ in nine open chest anesthetized mongrel dogs under eight different inotropic stages before and after ligation of left anterior descending (LAD, n=6) or circumflex coronary artery (LCX, n=3). We measured LV pressure simultaneously with a high-fidelity pressure catheter and calculated LV ejection fraction (EF) with the biplane Simpson’s method. Maximal positive dP/dt (dP/dt max ) was used as the gold standard measurement of LV contractility. We compared AR and S′ and EF against dP/dt max by linear regression. Both S′ and AR showed dose-dependent increases and decreases following dobutamine and esmolol infusion, respectively. There was a stronger association between dP/dt max and AR (r=0.820, P &lt;0.001) and S′ (r=0.784, P &lt;0.001) than between dP/dt max and EF (r=0.567, P &lt;0.001), and this trend was more apparent with coronary ligation. There was also a good correlation between AR and S′ with (r=0.690, P &lt;0.001) and without (r=0.740, P &lt;0.001) coronary ligation. Both AR and S′ are effective noninvasive indices of global LV contractility irrespective of coronary ligation and have better accuracy than LV EF.
Galactosylated chitosan (GC)-graft-poly(vinyl pyrrolidone) (PVP) as hepatocyte-targeting DNA carrier
Authors: I.K. Park, J.E. Ihm, Y.H. Park, Y.J. Choi, S.I. Kim, W.J. Kim, T. Akaike, C.S. Cho
Journal: Journal of Controlled Release (2003)
Abstract 3489: Presence of Thoracic Aorta Calcification Predicts All Cause Mortality Independent of Traditional Cardiovascular Risk Factors and Coronary Artery Calcification
Authors: Khurram Nasir, Matthew J Budoff, Leslee J Shaw, Tracy Q Callister, John Rumberger, Orakzai Sarwar, Poalo Raggi, Daniel Berman, Roger S Blumenthal
Journal: Circulation (2007)

Background: Recent guidelines have suggested that presence of coronary artery calcium (CAC) is an independent marker of adverse cardiovascular disease (CVD) events and mortality. However the predictive value of thoracic aorta calcification (TAC) that can be additionally identified without further scanning during assessment of CAC is unknown. Method: We followed a cohort of 8418 asymptomatic individuals (mean age: 53 ± 10 years, 69% men) undergoing cardiac risk factor evaluation and coronary calcium testing with electron-beam CT for median period of 5.0 years. Multivariable Cox proportional hazards models were developed to predict all-cause mortality obtained from the National Death Index with presence of TAC. Results: 141 (2%) all cause deaths were recorded. Overall survival was 96.7% and 98.8% for subjects with and without detectable TAC (p &lt; 0.0001). As compared to those with absent TAC (reference group) the hazard ratio for mortality for subjects with TAC was 3.07 (95% CI: 2.20 – 4.38) in unadjusted analyses (table ). After taking into account age, gender and CVD risk factors the association was reduced to 1.77 (95% CI: 1.11–2.29). The association of TAC with mortality remained statistically significant even after taking into account CAC (table ), although TAC appeared to predict events more strongly in the absence of CAC (HR: 2.81; 95% CI: 1.17– 6.79, p = 0.02) than with CAC &gt; 0 (HR: 1.39; 95% CI: 0.93–2.08, p = 0.10). However the interaction term between TAC and CAC for mortality was not significant (p = 0.23). Conclusions: Presence of TAC was associated with all-cause mortality in our study. This relationship was independent of conventional CVD risk factors and CAC. Hazard Ratio for All Cause Mortality with Presence of Thoracic Aorta Calcification
Abstract 5057: Habitual Dietary Intake of Fatty Acids in Relation to Insulin Resistance among Japanese Adults
Authors: Takashi Muramatsu, Hiroshi Yatsuya, Kunihiro Matsushita, Hirotsugu Mitsuhashi, Hideaki Toyoshima, Toyoaki Murohara
Journal: Circulation (2008)

Background: Asians including Japanese are more susceptible to glucose intolerance or type 2 diabetes mellitus (DM) than Caucasians. However little is known about the effects of dietary fatty acid (FA) intake on insulin resistance (IR) in Japanese. Objective: Our aim was to investigate associations between IR and habitual dietary intake of FAs among middle-aged Japanese adults. Methods: We designed a cross-sectional survey of 3383 Japanese adults aged 35– 66 years. IR was measured with homeostasis model assessment (HOMA-R) and nutrient intake was estimated by a self-administered diet history questionnaire. All amounts of nutrients were energy-adjusted as the residuals from regression model. Results: Log-transformed HOMA-R had a significant negative correlation with polyunsaturated fatty acid (PUFA). Multivariate-adjusted regression analysis demonstrated that IR had a significant positive association with saturated fatty acid (SFA) and inverse associations with n-6 series PUFA independently of age, sex, BMI, lipid profiles, other macronutrients and lifestyle. Multivariate-adjusted odds ratios of IR, defined as a top quartile of HOMA-R distribution, across the quartiles of energy-adjusted intakes were 1.0, 0.89, 0.73 and 0.57 for linoleic acid ( P for trend = 0.007) and 1.0, 0.90, 0.68 and 0.61 for alpha-linolenic acid ( P for trend = 0.010), respectively. Marine-derived n-3 PUFA and the ratio of n-6 to n-3 PUFA had no consistent association with IR. Conclusions: Our cross-sectional data suggest that a modification of dietary fat intake to substitute PUFA, in particular linoleic acid and alpha-linolenic acid, for SFA may have a clinical efficacy to prevent IR among a Japanese population.
Prognostic Value of 64-Slice Cardiac Computed Tomography
Authors: Benjamin J.W. Chow, George A. Wells, Li Chen, Yeung Yam, Paul Galiwango, Arun Abraham, Tej Sheth, Carole Dennie, Rob S. Beanlands, Terrence D. Ruddy
Journal: Journal of the American College of Cardiology (2010)
Abstract 9052: A Validation Study of Right Ventricular Stroke Volume Determination by 3D Echocardiography
Authors: Cole Streiff, Galym Imanbayev, Ana Badua, Sydney Prescott, Rohini Deb, Cong Tin P Le, Minjuan Zheng, Pengyuan Zhang, Xiaokui Li, David J Sahn
Journal: Circulation (2010)

Background: The volume of the right ventricle (RV) is difficult to evaluate due to its inherent geometry. This study aimed to validate the accuracy as well as the precision of cavity volume and str...
Abstract 3241: Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison of Serial Angiographic Follow-Up with Sirolimus, Paclitaxel, Zotarolimus and Tacrolimus-Eluting Stent: Multicenter Registry in Asia
Authors: Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul
Journal: Circulation (2006)
Comparison of Vascular Response After Sirolimus-Eluting Stent Implantation Between Patients With Unstable and Stable Angina Pectoris
Authors: Takashi Kubo, Toshio Imanishi, Hironori Kitabata, Akio Kuroi, Satoshi Ueno, Takashi Yamano, Takashi Tanimoto, Yoshiki Matsuo, Takashi Masho, Shigeho Takarada, Atsushi Tanaka, Nobuo Nakamura, Masato Mizukoshi, Yoshiaki Tomobuchi, Takashi Akasaka
Journal: JACC. Cardiovascular imaging (2008)
Inhibition of pancreatic tumor growth and progression by a human monoclonal antibody specific for connective tissue growth factor
Authors: S. M. Spong, N. Dornhofer, C. Wong, E. Lomongsod, A. Salim, Q. Le, A. Koong, S. Klaus, A. Giaccia
Journal: Journal of Clinical Oncology (2005)

4150 Background: Connective Tissue Growth Factor (CTGF) is a member of the CCN family of cysteine- rich secreted glycoproteins and is a novel factor recently implicated in tumor progression of several distinct tumor cell types. Elevated CTGF expression levels are correlated with tumor stage and poor prognosis in humans and CTGF expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. Methods: To directly address the role of CTGF in pancreatic cancer, we generated pancreatic tumor cell lines that over-express different levels of human CTGF. The effect of CTGF over-expression or inhibition of CTGF with a human monoclonal antibody, on cell proliferation was measured in vitro in monolayer cultures or soft agar assays and in vivo in tumor xenograft studies. Results: CTGF over-expression did not enhance proliferation of cells plated on plastic in two-dimensional cultures but in contrast, markedly enhanced the ability of cells to proliferate in anchorage-independent growth (AIG) assays when cells were plated in soft agar. Consistent with this finding, a neutralizing monoclonal antibody (mAb) specific for CTGF blocked anchorage-independent growth but had no effect on anchorage-dependent cell proliferation. The capacity of CTGF to enhance AIG in vitro led to enhanced tumor growth in vivo when these cells were implanted sub-cutaneously in standard xenograft models. Thus, compared to vector control transfectants that do not express CTGF, CTGF over-expressing cells exhibited enhanced tumor growth where tumor size correlated with CTGF over-expression in vitro. Elevated CTGF expression levels also correlated with increased mortality. Administration of a CTGF-specific mAb to mice with established CTGF expressing tumors abrogated CTGF-dependent tumor growth. A preliminary analysis of circulating CTGF levels in human pancreatic cancer patients indicates higher levels of CTGF as compared to normal subjects. Conclusions: Together these studies implicate CTGF as a novel target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may be a promising new therapy for this disease. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration FibroGen FibroGen FibroGen
Effect of Prolonged Ingestion of Thiourea on Mammary Glands and the Appearance of Mammary Tumors in Adult C3H Mice&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: Harold P. Morris, Celia S. Dubnik, Albert J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1946)

Effect of Prolonged Ingestion of Thiourea on Mammary Glands and the Appearance of Mammary Tumors in Adult C3H Mice Get access Harold P. Morris, Harold P. Morris senior nutrition chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Celia S. Dubnik, Celia S. Dubnik junior chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert J. Dalton Albert J. Dalton senior cytologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 3, December 1946, Pages 159–169, https://doi.org/10.1093/jnci/7.3.159 Published: 01 December 1946 Article history Received: 20 August 1946 Published: 01 December 1946
Relevance of screening on the colorectal cancer population.
Authors: E. Una Cidon
Journal: Journal of Clinical Oncology (2010)

e14119 Background: Colorectal cancer (CRC) is a leading cause of cancer incidence/death worldwide. Increased screening has reduced the incidence. But continued efforts are necessary to maintain this trend. The main problem is low popularity of screening. We aimed to know and quantify the relative importance of screening in a population of colorectal cancer patients (CRC). Methods: We designed a retrospective/descriptive study to evaluate medical records of CRC or recto- sigmoid junction (RSJ) at our Institution over 2004-2006. This study was approved by the institutional Ethic Committee. Results: 678 patients evaluated/668 eligible. 403 males/265 females. Median age: 66 (range 32-87 years). Globally 65% CC/35% had rectum/RSJ cancer. Diagnosed (D) by screening: 25 (3.7%) (16 CC and 9 rectum/RSJ), with 19 to be considered high risk and 6 during endoscopic revisions made by other gastrointestinal diseases (GID). 68 D asymptomatic during testing for other processes (49 CC/19 rectum-RSJ). 575 (65% CC/35% rectum/RSJ) by alarm symptoms (rectal bleeding, obstruction). Locations in colon: sigma (38%), followed by cecum (27%). Tumor endoscopic appearance: ulcerated 68%, stenosing 26% and polipoid 6%. Of overall CRC population 68% had synchronous polyps. Stage (S) distribution is shown in the Table. CRC over 50 years (587): 2% D during screening by symptoms suggesting other GID. Globally 2% D during screening to be consider of high risk. No patient underwent screening for average risk over 50 years. Conclusions: Our results are disappointing because the majority of CRC population is D by symptoms with higher rate of advanced stages than the screening population. Joint efforts with health authorities are required to ensure greater compliance with screening methods. Also it is neccessary to expand research in this field to implement effective measures most popular. Staging distribution in this population at the time of diagnosis N S I S II S III S IV Asymptomatic D 93 22 18 33 20 Screening 25 16 7 2 0 Others 68 6 11 31 20 Symptomatic D 575 116 208 144 107 CC 439 86 163 103 87 20% Rectum/RSJ 229 52 63 74 40 17% Overall 668 138 20.6% 226 33.8% 177 26.5% 127 19.1% No significant financial relationships to disclose.
Abstract 15501: The 5-Lipoxygenase Inhibitor Zileuton Improves Endothelial Function in Carriers of Coronary Heart Disease Risk Haplotypes in the ALOX5AP and LTA4H Leukotriene Pathway Genes
Authors: Riyaz S Patel, Hamid Syed, Raul R Blanco, Ibhar Al Mheid, Salman Sher, Danny J Eapen, Vivek Menon, Suliman Alradawi, Wei Li, A Maziar Zafari, Arshed A Quyyumi
Journal: Circulation (2011)

Background: Genome wide linkage studies have identified variants in the leukotriene synthesis pathway as conferring risk of coronary heart disease (CHD) and are associated with greater levels of th...
Abstract 17962: Acute Kidney Injury Increases Morbidity and Mortality After Surgery for Acute Type A Aortic Dissection
Authors: Yusuke Sasabuchi, Naoyuki Kimura, Tetsu Onuma, Junji Shiotsuka, Kayo Asaka, Koichi Adachi, Koichi Yuri, Harunobu Matsumoto, Atsushi Yamaguchi, Alan Lefor, Masamitsu Sanui, Hideo Adachi
Journal: Circulation (2012)

Background: Acute kidney injury (AKI) following cardiac surgery has been reported to increase morbidity and mortality. Acute type A aortic dissection (AAAD) remains a serious cardiovascular disease...
Safety and Efficacy of Commercially Available Ultrasound Contrast Agents for Rest and Stress Echocardiography
Authors: Melda S. Dolan, Simil S. Gala, Saritha Dodla, Sahar S. Abdelmoneim, Feng Xie, David Cloutier, Michelle Bierig, Sharon L. Mulvagh, Thomas R. Porter, Arthur J. Labovitz
Journal: Journal of the American College of Cardiology (2008)
Capecitabine monotherapy for patients with brain metastases from advanced breast cancer
Authors: D. R. Naskhletashvili, V. A. Gorbounova, M. B. Bychkov, G. E. Chmutin, V. B. Karakhan, V. B. Krat
Journal: Journal of Clinical Oncology (2009)

1102 Background: To assess the efficacy of capecitabine monotherapy for patients with chemotherapy-pretreated advanced breast cancer with brain metastases. Methods: Patients with brain metastases from breast cancer whose disease had progressed on prior chemotherapy for advanced disease received oral capecitabine 1,000 mg/m 2 bid on days 1–14 every 3 weeks until disease progression. Results: Between July 2007 and August 2008, 10 women were treated. Median age was 50 years (range 36–66 years). ECOG performance status was 1 in 7 patients and 2 in 3 patients. All had received prior chemotherapy: one line in five patients; two lines in four patients; three lines in one patient. Six patients had received prior endocrine therapy and three had received prior salvage radiotherapy to the brain. Two patients had metastases limited to the brain and the remaining eight also had extracranial metastases. All patients were assessable for response. Six achieved a partial response in the brain (CT/enhanced-contrast MRI), three showed disease stabilization, and one had disease progression as best response. Median duration of response was 4 months and median time to progression was 6 months. Seven patients are still alive and therefore median overall survival has not been reached. A total of 58 cycles of capecitabine were delivered. The most common toxicities (% of cycles) were neutropenia (G1/2 43.1%, G3/G4 8.6%), hand-foot syndrome (G1/2 25.9%, G3 8.6%), anemia (G1/2 29.3%, G3 1.7%), diarrhea (G1/2 20.6%, G3 5.2%), nausea/vomiting (G1/2 24.1%), stomatitis (G1/2 12%), thrombocytopenia (G1 8.6%), and fatigue (G1/2 6.9%). Conclusions: Our small study suggests that capecitabine has pronounced anticancer activity in patients with brain metastases from breast cancer with reasonable tolerability and easy administration as outpatient treatment. Further investigation is warranted. No significant financial relationships to disclose.
Abstract 2292: Negative Microvolt T Wave Alternans Test Results after Antiarrhythmic Drugs do not Predict Recurrence of Ventricular Tachycardia
Authors: Kaoru Tanno, Haruyuki Ito, Fumito Miyoshi, Yoshino Minoura, Mitsuharu Kawamura, Taku Asano, Youichi Kobayashi
Journal: Circulation (2006)

Microvolt T-wave alternans (MTWA) is reported to be closely associated with sudden cardiac death and ventricular tachyarrhythmia (VT) in patients with organic heart disease (OHD). The purpose of th...
Abstract 15600: Mechanisms of Anti-Arrhythmic Effects of Progesterone and Pro-Arrhythmic Effects of Estradiol in Transgenic Long QT Type 2 Rabbits
Authors: Katja E Odening, Bum R Choi, Gong X Liu, Kathryn M Hartmann, Leonard Chaves, Lorraine Schofield, Michael Brunner, Manfred Zehender, Xuwen Peng, Gideon Koren
Journal: Circulation (2010)
Abstract 15828: No Persistent Significant Risks Observed With Both Thoracic and Non-Thoracic Magnetic Resonance Imaging in the Presence of Implanted Cardiac Rhythm Devices
Authors: Jeffrey S Osborn, Thomas J Bunch, Steve Mason, Brian G Crandall, John D Day, J. P Weiss, Donald L Lappe, Joseph B Muhlestein, Jeffrey L Anderson
Journal: Circulation (2011)

Introduction: Magnetic resonance imaging (MRI) may provide important and potentially life-saving information for patients with implanted cardiac devices. A protocol was developed at the Intermounta...
Common sense, nonsense and statistics
Authors: Nick Lane
Journal: Journal of the Royal Society of Medicine (1999)

The media has recently been echoing a claim that medical statistics too frequently inspire cries of 'breakthrough!' later exposed in the cold light of experience, as nothing but mirages. The arbitrary parameters and potential subjectivity of conventional medical statistics have been debated, without consensus, in most of the major journals. The question stands: do we allow conventional medical statistics to bias our interpretation of the true significance of medical research? Undoubtedly, some form of statistics is needed to help interpret the results of clinical trials. The problem is the cut-off point: what qualifies as an important finding? For years, conference halls have rung with sceptical voices questioning the clinical relevance of statistically significant data. Neither P values nor confidence intervals seem consistently reliable as a guide to clinical significance. Moreover, the assumptions underlying parametric significance tests (such as equality of variance in group comparisons) may be untrue of some studies. A systematic approach often put forward to correct for subjectivity bias (prior probability) among clinical investigators is Bayesian analysis. We are told that elimination of subjectivity by use of Bayesian inference paves the way to truly objective, evidence-based medical practice. Yet who but a statistically minded minority can begin to interpret Bayesian analysis? Reading various exchanges of letters in the medical journals on statistical models, I am struck by the fact that almost all are written by biostatisticians. The opinions of practising physicians are deafeningly silent. In our mounting enthusiasm for evidence-based medicine, we may be giving too much weight to clumsy statistical formulations that should not hinge our judgment of clinical relevance. In this article I suggest, firstly, that conventional medical statistics are better than more sophisticated alternatives since they are better understood by practising physicians; and, secondly, that the problems we have with statistics derive less from our methodology than from our stiff conventions of interpretation.